Clinical Trials on Myelodysplastic Syndrome With Excess Blasts

Total 2852 results

University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States
Groupe Francophone des Myelodysplasies
Aprea Therapeutics

Unknown

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene Mutation

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Untreated Adult Acute Myeloid... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome and other conditions

United States
Centre Hospitalier Universitaire de Nice

Unknown

Characterization of the Mechanisms of Resistance to Azacitidine

Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia

France, Monaco
University of Southern California
National Cancer Institute (NCI); Van Andel Research Institute

Active, not recruiting

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Myelodysplastic Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Completed

Belinostat in Treating Patients With Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Celgene Corporation

Completed

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

United States
Roswell Park Cancer Institute
Jazz Pharmaceuticals

Recruiting

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
National Cancer Institute (NCI)

Completed

A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
TJ Biopharma Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes(MDS)

China
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)

Recruiting

The National Myelodysplastic Syndromes (MDS) Study (MDS)

Myelodysplastic Syndromes (MDS)

United States, Israel
AbbVie
Celgene; Genentech, Inc.

Completed

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States, Australia, Germany
AbbVie
Genentech, Inc.

Active, not recruiting

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States, Australia, Canada, France, Germany, Italy, United Kingdom
The First Affiliated Hospital with Nanjing Medical...

Unknown

A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
SCRI Development Innovations, LLC
Novartis Pharmaceuticals

Terminated

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States
PersImmune, Inc
University of California, San Diego

Unknown

Collection of Samples From Patients With MDS

Myelodysplastic Syndromes(MDS)

United States
Brian Jonas
National Cancer Institute (NCI); Celgene; Pharmacyclics LLC.

Completed

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
Dana-Farber Cancer Institute

Completed

The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study

Myelodysplastic Syndromes (MDS)

United States
Roswell Park Cancer Institute
Celldex Therapeutics

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated Cells

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia,...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab in AML in Remission at High Risk for Relapse

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Blasts Under 10 Percent of Bone Marrow Nucleated Cells | Therapy-Related Myeloid Neoplasm

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

Severe Aplastic Anemia (SAA) | Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Terminated

Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditions

Canada
Merck Sharp & Dohme LLC

Terminated

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic | Myelodysplasia | Myelomonocytic
Dana-Farber Cancer Institute
Stemline Therapeutics, Inc.

Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
David Iberri

Terminated

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults | AML (Adult) With 11q23 (MLL) Abnormalities | AML (Adult) With Del (5q) | AML (Adult) With Inv (16) (p13; q22) | AML (Adult) With t (16;16) (p13; q22) | AML (Adult) With t (8; 21) (q22; q22) and other conditions

United States
Sheba Medical Center
Hadassah Medical Organization; Kaplan Medical Center; Tel Aviv Medical Center; Ziv...

Completed

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Myelodysplastic Syndrome With Low-grade Lesions | Iron Overload Due to Repeated Red Blood Cell Transfusions

Israel
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...

United States
National Cancer Institute (NCI)

Completed

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome With Isolated Del(5q)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Therapy-Related Acute Myeloid Leukemia and other conditions

United States
Radboud University Medical Center

Recruiting

A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (EUMDS)

Myelodysplastic Syndromes (MDS)

Denmark, Switzerland, Serbia, Austria, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, United Kingdom
Takeda

Withdrawn

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes (PEVOBINE)

Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
Prof. Janet Dunn
King's College Hospital NHS Trust; University of Manchester; University of Birmingham and other collaborators

Recruiting

Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes (REPAIR-MDS)

Myelodysplastic Syndromes (MDS)

United Kingdom
University of Texas Southwestern Medical Center

Completed

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Thomas Jefferson University
AbbVie

Recruiting

Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astellas Pharma Inc

Completed

Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute... and other conditions

United States
Akeso

Recruiting

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Higher-risk Myelodysplastic Syndromes

United States, China
Nuwacell Biotechnologies Co., Ltd.
The First Affiliated Hospital of University of Science and Technology of...

Not yet recruiting

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

Relapsed / Refractory Myelodysplastic Syndromes
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy

Previously Treated Myelodysplastic Syndromes

United States
University of Colorado, Denver

Active, not recruiting

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

High Grade Myelodysplastic Syndromes

United States
ALX Oncology Inc.

Active, not recruiting

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Higher Risk Myelodysplastic Syndromes

Korea, Republic of, United States, Spain
Rigel Pharmaceuticals

Recruiting

Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)

Low Risk Myelodysplastic Syndromes

United States
Bristol-Myers Squibb

Active, not recruiting

Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan

Lower-risk Myelodysplastic Syndromes

Japan

Clinical Trials on Myelodysplastic Syndrome With Excess Blasts

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations